B型肝炎ウイルス（HBV）の世界市場レポート 2024年

B型肝炎ウイルス（HBV）の市場規模は近年急速に拡大しています。2023年の60億4,000万米ドルから2024年には67億1,000万米ドルへとCAGR11.1％で拡大します。この実績期間の成長は、B型肝炎ウイルス（HBV）の有病率の上昇、hbv診断薬に対する需要の拡大、hbvワクチン接種率の拡大、B型肝炎ウイルス（HBV）に対する意識の高まりに起因しています。

肝障害または肝硬変に罹患する患者の発生率の上昇は、将来的にB型肝炎ウイルス市場の成長を促進すると予想されます。肝硬変は、健康な肝組織が瘢痕組織に永久的に置き換わることを特徴とする重篤な肝疾患です。B型肝炎ウイルスは、肝疾患の症状や副作用を緩和する一方で、腎機能に影響を与えることにより、肝疾患患者に大きな影響を与える役割を担っています。例えば、米国疾病予防管理センターが2022年9月に発表したファクトシートによると、米国で肝疾患と診断された成人は450万人でした。さらに、医療情報サイト「Medscape」のデータによると、アルコール性肝疾患（ALD）関連の死亡者数は2019年から2021年の間に17.6％増加し、非アルコール性脂肪性肝疾患（NAFLD）関連の死亡者数は14.5％増加しました。その結果、肝障害や肝硬変を経験する患者数の増加がB型肝炎ウイルス市場の拡大に拍車をかけています。

2023年のB型肝炎ウイルス（HBV）市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。B型肝炎ウイルス（HBV）レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のB型肝炎ウイルス（HBV）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 急性
• 慢性
• 世界のB型肝炎ウイルス（HBV）市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 免疫調節薬
• 抗ウイルス薬
• ワクチン
• 手術
• 世界のB型肝炎ウイルス（HBV）市場、年齢層別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 小児
• 大人
• シニア
• 世界のB型肝炎ウイルス（HBV）市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 医療提供者
• 患者
• ヘルスケア支払者

第7章 地域および国の分析

• 世界のB型肝炎ウイルス（HBV）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のB型肝炎ウイルス（HBV）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• B型肝炎ウイルス（HBV）市場の競合情勢
• B型肝炎ウイルス（HBV）市場企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F. Hoffmon La Roche Ltd.
  • Merck &Co. Inc.
  • AbbVie Inc.

第31章 その他の主要および革新的な企業

• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi SA
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated
• Eisai Co. Ltd.
• Aurobindo Pharma Limited
• Apotex Corp.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Hepatitis B Virus (HBV) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis b virus (hbv)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hepatitis b virus (hbv) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Acute; Chronic
• 2) By Treatment: Immune Modulator Drugs; Antiviral Drugs; Vaccine; Surgery
• 3) By Age Group: Pediatrics; Adults; Seniors
• 4) By End User: Medical Providers; Patients; Healthcare Payers
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmon La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hepatitis B virus (HBV) is a liver-targeting viral infection transmitted through contact with infected blood or bodily fluids, including vertical transmission from mother to child during childbirth. The primary approach to managing HBV involves the use of antiviral medications to suppress viral replication, while vaccination plays a crucial role in prevention.

Hepatitis B virus (HBV) is categorized into acute and chronic forms. Acute hepatitis B is a short-term infection resulting from HBV, typically occurring within the first six months of exposure. The medications for acute cases aim to clear the virus from the body and prevent chronic infection. Treatment options include immune modulator drugs, antiviral medications, vaccines, and, in some cases, surgery. These treatments are administered to individuals across various age groups, including pediatrics, adults, and seniors, with medical providers, patients, and healthcare payers being involved in the healthcare process.

The hepatitis B virus (HBV) market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) market statistics, including hepatitis B virus (HBV) industry global market size, regional shares, competitors with a hepatitis B virus (HBV) market share, detailed hepatitis B virus (HBV) market segments, market trends and opportunities and any further data you may need to thrive in the hepatitis B virus (HBV) industry. This hepatitis B virus (HBV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis b virus (hbv) market size has grown rapidly in recent years. It will grow from $6.04 billion in 2023 to $6.71 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising prevalence of hepatitis b virus (hbv), growing demand for hbv diagnostics, expanding hbv vaccine coverage, rising awareness of hepatitis b virus (hbv).

The hepatitis b virus (hbv) market size is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rise of personalized medicine, growing support from patient advocacy groups, rising vaccination programs, increase in healthcare expenditure. Major trends in the forecast period include development of new drugs, advancements in diagnostic technologies, public-private partnerships, innovative biological therapies.

The heightened prevalence of hepatitis B infection is anticipated to drive the growth of the hepatitis B virus market in the foreseeable future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), and it can be prevented through vaccination. The increasing rates of hepatitis B infections are likely to result in greater demand for diagnostic tests and treatment options. For example, data from December 2022, sourced from the European Centre for Disease Prevention and Control, an organization based in Sweden dedicated to enhancing Europe's defenses against infectious diseases, revealed that there were 16,187 recorded cases of hepatitis B virus (HBV) infection in 30 Eastern European Member States in 2021. Additionally, the total number of cases, 15,380, corresponded to a crude rate of 4.7 cases per 100,000 people, compared to 14,332 cases in 2020. Consequently, the substantial prevalence of hepatitis B infection is poised to be a driving force behind the hepatitis B virus market's growth.

The rising incidence of patients suffering from liver damage or cirrhosis is expected to drive the growth of the hepatitis B virus market in the future. Cirrhosis is a severe form of liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. The hepatitis B virus plays a significant role in impacting patients with liver disease by affecting kidney function while mitigating symptoms and adverse effects of the disorder. For instance, according to a Fact Sheet published by the Centers for Disease Control and Prevention in September 2022, there were 4.5 million adults diagnosed with liver disease in the United States. Additionally, data from Medscape, a medical information website, shows that fatalities related to alcoholic liver disease (ALD) increased by 17.6% between 2019 and 2021, while non-alcoholic fatty liver disease (NAFLD)-related deaths rose by 14.5%. As a result, the growing number of patients experiencing liver damage or cirrhosis is fueling the expansion of the hepatitis B virus market.

The growth of the hepatitis B virus (HBV) market in the forecast period may face constraints due to the increasing healthcare expenditure. While HBV screening is considered cost-effective, the rising costs in healthcare could limit the availability of point-of-care hepatitis B surface antigen tests in countries with limited resources. This situation could potentially lead to delays in patient care and reduced access to essential diagnostics. For example, in the UK, healthcare spending increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. Additionally, preventive care spending more than doubled from 2020 to 2021. Consequently, the upward trend in healthcare expenditure could pose challenges to the growth of the hepatitis B virus (HBV) market in the future.

Prominent companies operating within the hepatitis B virus (HBV) market are placing a strong emphasis on the advancement of cutting-edge diagnostics and treatment options. One such innovation involves the utilization of highly sensitive chemiluminescent microparticle immunoassay (CMIA) technology to gain a competitive edge in the market. A case in point is Abbott Laboratories, a healthcare company based in the United States, which, in May 2022, introduced the HBsAg Next Qualitative Solution Test. This test is designed to facilitate the early detection of the Hepatitis B virus (HBV) in human serum and plasma samples. By enhancing early detection capabilities, this advanced chemiluminescent microparticle immunoassay (CMIA) not only contributes to improved patient outcomes but also safeguards the integrity of blood supplies. It enables both early detection of HBV in human serum and plasma (blood) samples and population screening, all thanks to its highly sensitive technology.

In July 2023, Brii Biosciences Ltd., a biotechnology firm headquartered in China, secured licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc., an American biotechnology company. This transaction, for an undisclosed sum, grants Brii Biosciences Ltd. access to valuable insights related to both the prevention and treatment of hepatitis B. VBI Vaccines Inc. specializes in the development of a vaccine designed to prevent infections caused by the hepatitis B virus.

Major players in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hepatitis B Virus (HBV) Market Characteristics

3. Hepatitis B Virus (HBV) Market Trends And Strategies

4. Hepatitis B Virus (HBV) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Hepatitis B Virus (HBV) Market Size and Growth

• 5.1. Global Hepatitis B Virus (HBV) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hepatitis B Virus (HBV) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hepatitis B Virus (HBV) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hepatitis B Virus (HBV) Market Segmentation

• 6.1. Global Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Acute
• Chronic
• 6.2. Global Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immune Modulator Drugs
• Antiviral Drugs
• Vaccine
• Surgery
• 6.3. Global Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pediatrics
• Adults
• Seniors
• 6.4. Global Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medical Providers
• Patients
• Healthcare Payers

7. Hepatitis B Virus (HBV) Market Regional And Country Analysis

• 7.1. Global Hepatitis B Virus (HBV) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hepatitis B Virus (HBV) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hepatitis B Virus (HBV) Market

• 8.1. Asia-Pacific Hepatitis B Virus (HBV) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hepatitis B Virus (HBV) Market

• 9.1. China Hepatitis B Virus (HBV) Market Overview
• 9.2. China Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hepatitis B Virus (HBV) Market

• 10.1. India Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hepatitis B Virus (HBV) Market

• 11.1. Japan Hepatitis B Virus (HBV) Market Overview
• 11.2. Japan Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hepatitis B Virus (HBV) Market

• 12.1. Australia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hepatitis B Virus (HBV) Market

• 13.1. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hepatitis B Virus (HBV) Market

• 14.1. South Korea Hepatitis B Virus (HBV) Market Overview
• 14.2. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hepatitis B Virus (HBV) Market

• 15.1. Western Europe Hepatitis B Virus (HBV) Market Overview
• 15.2. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hepatitis B Virus (HBV) Market

• 16.1. UK Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hepatitis B Virus (HBV) Market

• 17.1. Germany Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hepatitis B Virus (HBV) Market

• 18.1. France Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hepatitis B Virus (HBV) Market

• 19.1. Italy Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hepatitis B Virus (HBV) Market

• 20.1. Spain Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hepatitis B Virus (HBV) Market

• 21.1. Eastern Europe Hepatitis B Virus (HBV) Market Overview
• 21.2. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hepatitis B Virus (HBV) Market

• 22.1. Russia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hepatitis B Virus (HBV) Market

• 23.1. North America Hepatitis B Virus (HBV) Market Overview
• 23.2. North America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hepatitis B Virus (HBV) Market

• 24.1. USA Hepatitis B Virus (HBV) Market Overview
• 24.2. USA Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hepatitis B Virus (HBV) Market

• 25.1. Canada Hepatitis B Virus (HBV) Market Overview
• 25.2. Canada Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hepatitis B Virus (HBV) Market

• 26.1. South America Hepatitis B Virus (HBV) Market Overview
• 26.2. South America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hepatitis B Virus (HBV) Market

• 27.1. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hepatitis B Virus (HBV) Market

• 28.1. Middle East Hepatitis B Virus (HBV) Market Overview
• 28.2. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hepatitis B Virus (HBV) Market

• 29.1. Africa Hepatitis B Virus (HBV) Market Overview
• 29.2. Africa Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hepatitis B Virus (HBV) Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis B Virus (HBV) Market Competitive Landscape
• 30.2. Hepatitis B Virus (HBV) Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmon La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Hepatitis B Virus (HBV) Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Sanofi SA
• 31.5. GlaxoSmithKline PLC
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Mylan N.V.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Vertex Pharmaceuticals Incorporated
• 31.13. Eisai Co. Ltd.
• 31.14. Aurobindo Pharma Limited
• 31.15. Apotex Corp.

32. Global Hepatitis B Virus (HBV) Market Competitive Benchmarking

33. Global Hepatitis B Virus (HBV) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Market

35. Hepatitis B Virus (HBV) Market Future Outlook and Potential Analysis

• 35.1 Hepatitis B Virus (HBV) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Hepatitis B Virus (HBV) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Hepatitis B Virus (HBV) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer